NASDAQ:FLXN - Flexion Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$27.69 +0.20 (+0.73 %)
(As of 05/22/2018 09:59 AM ET)
Previous Close$27.49
Today's Range$27.50 - $27.76
52-Week Range$16.51 - $32.25
Volume59,592 shs
Average Volume553,414 shs
Market Capitalization$1.04 billion
P/E Ratio-6.66
Dividend YieldN/A
Beta0.82

About Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics logoFlexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee. The company also develops FX101 and FX201, which is a pre-clinical stage programs for the treatment OA of large joints. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.

Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FLXN
CUSIPN/A
Phone781-305-7777

Debt

Debt-to-Equity Ratio0.67
Current Ratio15.57
Quick Ratio15.47

Price-To-Earnings

Trailing P/E Ratio-6.66
Forward P/E Ratio-5.84
P/E GrowthN/A

Sales & Book Value

Annual Sales$350,000.00
Price / Sales2,977.86
Cash FlowN/A
Price / CashN/A
Book Value$6.93 per share
Price / Book4.00

Profitability

EPS (Most Recent Fiscal Year)($4.16)
Net Income$-137,480,000.00
Net MarginsN/A
Return on Equity-72.18%
Return on Assets-39.69%

Miscellaneous

Employees251
Outstanding Shares37,640,000

Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics (NASDAQ:FLXN) released its quarterly earnings data on Tuesday, May, 8th. The specialty pharmaceutical company reported ($1.10) EPS for the quarter, beating analysts' consensus estimates of ($1.33) by $0.23. The specialty pharmaceutical company earned $2.19 million during the quarter, compared to the consensus estimate of $1.99 million. View Flexion Therapeutics' Earnings History.

What price target have analysts set for FLXN?

9 brokerages have issued twelve-month target prices for Flexion Therapeutics' stock. Their predictions range from $36.00 to $570.00. On average, they anticipate Flexion Therapeutics' share price to reach $99.00 in the next twelve months. View Analyst Ratings for Flexion Therapeutics.

Who are some of Flexion Therapeutics' key competitors?

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the folowing people:
  • Dr. Michael D. Clayman, Co-Founder, Pres, CEO, Principal Financial & Accounting Officer and Director (Age 66)
  • Dr. Neil Bodick M.D., Ph.D., Co-Founder & Chief Scientific Officer (Age 71)
  • Mr. Frederick W. Driscoll, Advisor (Age 67)
  • Scott Young, Sr. Director of Corp. Communications & Investor Relations
  • Ms. Carolyn Beaty Scimemi Esq., Chief Compliance Officer

Has Flexion Therapeutics been receiving favorable news coverage?

Media stories about FLXN stock have trended somewhat positive recently, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Flexion Therapeutics earned a news impact score of 0.14 on Accern's scale. They also gave media stories about the specialty pharmaceutical company an impact score of 47.81 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Flexion Therapeutics' major shareholders?

Flexion Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.94%), Rubric Capital Management LP (5.38%), Wells Fargo & Company MN (4.46%), Millennium Management LLC (1.84%), Wasatch Advisors Inc. (1.68%) and Schroder Investment Management Group (1.36%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Institutional Ownership Trends for Flexion Therapeutics.

Which institutional investors are selling Flexion Therapeutics stock?

FLXN stock was sold by a variety of institutional investors in the last quarter, including Bamco Inc. NY, BlackRock Inc., Wasatch Advisors Inc., Wells Fargo & Company MN, JPMorgan Chase & Co., Gagnon Securities LLC, Allianz Asset Management GmbH and Schroder Investment Management Group. View Insider Buying and Selling for Flexion Therapeutics.

Which institutional investors are buying Flexion Therapeutics stock?

FLXN stock was bought by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Millennium Management LLC, UBS Group AG, California Public Employees Retirement System, Trexquant Investment LP, Wexford Capital LP, Cubist Systematic Strategies LLC and DekaBank Deutsche Girozentrale. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Insider Buying and Selling for Flexion Therapeutics.

How do I buy shares of Flexion Therapeutics?

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $27.69.

How big of a company is Flexion Therapeutics?

Flexion Therapeutics has a market capitalization of $1.04 billion and generates $350,000.00 in revenue each year. The specialty pharmaceutical company earns $-137,480,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Flexion Therapeutics employs 251 workers across the globe.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]


MarketBeat Community Rating for Flexion Therapeutics (FLXN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  332 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  493
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe FLXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLXN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Flexion Therapeutics (NASDAQ:FLXN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Flexion Therapeutics in the last 12 months. Their average twelve-month price target is $99.00, suggesting that the stock has a possible upside of 257.53%. The high price target for FLXN is $570.00 and the low price target for FLXN is $36.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.892.892.893.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $99.00$99.00$99.1111$98.3333
Price Target Upside: 257.53% upside303.26% upside338.74% upside309.89% upside

Flexion Therapeutics (NASDAQ:FLXN) Consensus Price Target History

Price Target History for Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics (NASDAQ:FLXN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/5/2018Wells FargoReiterated RatingBuyLowView Rating Details
3/9/2018BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$37.00 ➝ $36.00LowView Rating Details
2/1/2018Berenberg BankInitiated CoverageBuy$42.00HighView Rating Details
11/10/2017Northland SecuritiesReiterated RatingBuy$40.00N/AView Rating Details
10/29/2017Royal Bank of CanadaSet Price TargetBuy$44.00N/AView Rating Details
10/10/2017LaidlawReiterated RatingBuy$35.00 ➝ $38.00N/AView Rating Details
10/10/2017Janney Montgomery ScottBoost Price TargetBuy ➝ Fair Value$570.00N/AView Rating Details
10/9/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$36.00 ➝ $42.00N/AView Rating Details
6/12/2017Cantor FitzgeraldSet Price TargetBuy$40.00LowView Rating Details
12/22/2016Raymond JamesInitiated CoverageStrong-Buy$35.00N/AView Rating Details
11/8/2016BCSLower Price Target$0.65 ➝ $0.02N/AView Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$38.00N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Flexion Therapeutics (NASDAQ:FLXN) Earnings History and Estimates Chart

Earnings by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics (NASDAQ:FLXN) Earnings Estimates

Current Year EPS Consensus Estimate: $-4.74 EPS
Next Year EPS Consensus Estimate: $-2.74 EPS

Flexion Therapeutics (NASDAQ FLXN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($1.3270)($1.10)$1.99 million$2.19 millionViewN/AView Earnings Details
3/8/2018Q4 2017($1.1110)($1.38)$1.29 million$0.36 millionViewListenView Earnings Details
11/6/2017Q3 2017($0.98)($1.07)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.80)($0.91)ViewListenView Earnings Details
5/4/2017Q1 2017($0.73)($0.75)ViewListenView Earnings Details
3/9/2017Q4 2016($0.71)($0.7850)ViewListenView Earnings Details
11/7/2016Q3($0.63)($0.65)ViewListenView Earnings Details
8/3/2016Q2($0.67)($0.63)ViewN/AView Earnings Details
5/12/2016Q1($0.61)($0.78)ViewListenView Earnings Details
3/10/2016Q4 2015($0.58)($0.63)ViewN/AView Earnings Details
11/9/2015Q3($0.60)($0.52)ViewListenView Earnings Details
8/6/2015Q215($0.54)($0.58)ViewN/AView Earnings Details
5/7/2015Q115($0.56)($0.43)ViewN/AView Earnings Details
3/23/2015Q4 2014($0.46)($0.47)ViewN/AView Earnings Details
11/13/2014Q314($0.54)($0.45)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.55)($0.38)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.53)($0.86)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Flexion Therapeutics (NASDAQ:FLXN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Flexion Therapeutics (NASDAQ FLXN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.59%
Institutional Ownership Percentage: 97.05%
Insider Trading History for Flexion Therapeutics (NASDAQ:FLXN)
Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics (NASDAQ FLXN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2017Neil BodickInsiderBuy2,700$24.49$66,123.0064,605View SEC Filing  
11/8/2017Michael D ClaymanInsiderBuy5,000$23.60$118,000.0035,395View SEC Filing  
9/5/2017Yamo DenizInsiderBuy1,000$24.20$24,200.005,000View SEC Filing  
9/1/2017Yamo DenizInsiderBuy3,000$24.15$72,450.005,000View SEC Filing  
8/31/2017Yamo DenizInsiderBuy1,375$25.40$34,925.005,000View SEC Filing  
6/16/2017Mark StejbachDirectorBuy1,580$17.02$26,891.60View SEC Filing  
6/5/2017Michael D ClaymanInsiderBuy5,000$17.23$86,150.0020,146View SEC Filing  
4/17/2017Neil BodickInsiderSell5,000$28.23$141,150.0046,137View SEC Filing  
3/23/2017Frederick W DriscollCFOSell3,000$23.00$69,000.0010,777View SEC Filing  
3/17/2017Neil BodickInsiderSell5,000$20.41$102,050.0050,937View SEC Filing  
2/24/2017Neil BodickInsiderSell5,000$19.15$95,750.0055,937View SEC Filing  
1/20/2017Neil BodickInsiderSell5,000$18.35$91,750.0060,937View SEC Filing  
12/21/2016Neil BodickInsiderSell10,000$18.46$184,600.0065,937View SEC Filing  
12/1/2016Samuel D ColellaDirectorBuy10,000$16.38$163,800.0025,504View SEC Filing  
11/23/2016Michael D ClaymanInsiderBuy1,667$18.41$30,689.4730,721View SEC Filing  
11/22/2016Michael D ClaymanInsiderBuy1,666$17.95$29,904.7029,054View SEC Filing  
11/21/2016Michael D ClaymanInsiderBuy1,666$17.90$29,821.4027,388View SEC Filing  
11/21/2016Samuel D ColellaDirectorBuy33,333$18.00$599,994.0025,504View SEC Filing  
6/21/2016Samuel D ColellaDirectorBuy25,504$13.71$349,659.843,435View SEC Filing  
6/20/2016Samuel D ColellaDirectorBuy6,778$13.84$93,807.523,435View SEC Filing  
6/14/2016C Ann MerrifieldDirectorBuy1,000$13.39$13,390.002,000View SEC Filing  
6/8/2016Samuel D ColellaDirectorBuy714,285$14.00$9,999,990.00View SEC Filing  
5/20/2016Michael D ClaymanCEOBuy2,000$10.41$20,820.0013,568View SEC Filing  
5/19/2016Michael D ClaymanCEOBuy2,000$9.65$19,300.0011,568View SEC Filing  
5/19/2016Neil BodickInsiderBuy850$10.00$8,500.0075,937View SEC Filing  
5/18/2016Michael D ClaymanCEOBuy2,000$10.23$20,460.009,568View SEC Filing  
5/18/2016Neil BodickInsiderBuy2,100$10.20$21,420.0075,087View SEC Filing  
5/17/2016Frederick W DriscollCFOBuy2,500$9.87$24,675.008,434View SEC Filing  
5/17/2016Michael D ClaymanCEOBuy2,000$9.73$19,460.007,568View SEC Filing  
5/17/2016Neil BodickInsiderBuy800$9.60$7,680.0072,987View SEC Filing  
5/16/2016Frederick W DriscollCFOBuy2,500$9.19$22,975.005,934View SEC Filing  
5/16/2016Michael D ClaymanCEOBuy2,000$9.51$19,020.005,568View SEC Filing  
5/16/2016Neil BodickInsiderBuy1,250$9.22$11,525.0071,937View SEC Filing  
9/11/2015C Ann MerrifieldDirectorBuy1,000$23.00$23,000.001,000View SEC Filing  
6/22/2015A/S NovoMajor ShareholderSell150,000$20.61$3,091,500.00View SEC Filing  
3/16/2015Neil BodickInsiderSell4,000$25.28$101,120.00View SEC Filing  
3/10/2015Neil BodickInsiderSell4,000$24.26$97,040.00View SEC Filing  
3/4/2015Neil BodickInsiderSell4,000$23.45$93,800.00View SEC Filing  
2/26/2015Neil BodickInsiderSell4,000$22.44$89,760.00View SEC Filing  
12/17/2014A/S NovoMajor ShareholderBuy500,000$17.00$8,500,000.00View SEC Filing  
2/18/2014A/S NovoInsiderBuy692,308$13.00$9,000,004.00View SEC Filing  
2/18/2014Bradley J Phd BolzonDirectorBuy307,692$13.00$3,999,996.00View SEC Filing  
2/18/2014Sofinnova Partners SasMajor ShareholderBuy230,769$13.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Flexion Therapeutics (NASDAQ FLXN) News Headlines

Source:
DateHeadline
$3.96 Million in Sales Expected for Flexion Therapeutics (FLXN) This Quarter$3.96 Million in Sales Expected for Flexion Therapeutics (FLXN) This Quarter
www.americanbankingnews.com - May 22 at 2:50 AM
Zacks: Analysts Expect Flexion Therapeutics (FLXN) Will Announce Earnings of -$1.22 Per ShareZacks: Analysts Expect Flexion Therapeutics (FLXN) Will Announce Earnings of -$1.22 Per Share
www.americanbankingnews.com - May 20 at 5:16 PM
BidaskClub Upgrades Flexion Therapeutics (FLXN) to HoldBidaskClub Upgrades Flexion Therapeutics (FLXN) to Hold
www.americanbankingnews.com - May 19 at 1:01 PM
Flexion Therapeutics (FLXN) Given Average Rating of "Buy" by AnalystsFlexion Therapeutics (FLXN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 17 at 5:38 PM
Flexion Therapeutics (FLXN) Upgraded to Hold at Zacks Investment ResearchFlexion Therapeutics (FLXN) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 11 at 10:55 PM
BidaskClub Downgrades Flexion Therapeutics (FLXN) to SellBidaskClub Downgrades Flexion Therapeutics (FLXN) to Sell
www.americanbankingnews.com - May 11 at 8:05 PM
Edited Transcript of FLXN earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of FLXN earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 8:56 AM
Flexion Therapeutics (FLXN) Announces  Earnings ResultsFlexion Therapeutics (FLXN) Announces Earnings Results
www.americanbankingnews.com - May 9 at 1:34 PM
Flexion Therapeutics, Inc. (FLXN)Flexion Therapeutics, Inc. (FLXN)
seekingalpha.com - May 9 at 8:51 AM
Flexion Therapeutics (FLXN) CEO Michael Clayman on Q1 2018 Results - Earnings Call TranscriptFlexion Therapeutics (FLXN) CEO Michael Clayman on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:51 AM
Flexion Therapeutics: 1Q Earnings SnapshotFlexion Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:51 AM
Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business HighlightsFlexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights
finance.yahoo.com - May 8 at 5:07 PM
Traders Buy High Volume of Flexion Therapeutics Put Options (FLXN)Traders Buy High Volume of Flexion Therapeutics Put Options (FLXN)
www.americanbankingnews.com - May 8 at 6:52 AM
Flexion Therapeutics (FLXN) Names David Arkowitz as CFOFlexion Therapeutics (FLXN) Names David Arkowitz as CFO
www.streetinsider.com - May 7 at 8:45 AM
Flexion Therapeutics Names David Arkowitz as Chief Financial OfficerFlexion Therapeutics Names David Arkowitz as Chief Financial Officer
finance.yahoo.com - May 7 at 8:45 AM
Flexion Therapeutics (FLXN) Receives Buy Rating from Wells FargoFlexion Therapeutics (FLXN) Receives Buy Rating from Wells Fargo
www.americanbankingnews.com - May 6 at 12:01 PM
Flexion Therapeutics (FLXN) Expected to Post Quarterly Sales of $1.99 MillionFlexion Therapeutics (FLXN) Expected to Post Quarterly Sales of $1.99 Million
www.americanbankingnews.com - May 5 at 4:37 AM
Permanent reimbursement for Flexions Zilretta established in U.S.Permanent reimbursement for Flexion's Zilretta established in U.S.
seekingalpha.com - May 4 at 8:45 AM
2 Attractive Biotech Stocks To Buy Now2 Attractive Biotech Stocks To Buy Now
seekingalpha.com - May 3 at 4:59 PM
Zacks: Analysts Anticipate Flexion Therapeutics (FLXN) Will Post Earnings of -$1.35 Per ShareZacks: Analysts Anticipate Flexion Therapeutics (FLXN) Will Post Earnings of -$1.35 Per Share
www.americanbankingnews.com - May 3 at 5:32 AM
Flexion Therapeutics Announces Presentation of Positive FX201 Data at the Osteoarthritis Research Society ...Flexion Therapeutics Announces Presentation of Positive FX201 Data at the Osteoarthritis Research Society ...
globenewswire.com - April 30 at 4:54 PM
Flexion Therapeutics to Report First-Quarter 2018 Financial Results on May 8, 2018Flexion Therapeutics to Report First-Quarter 2018 Financial Results on May 8, 2018
globenewswire.com - April 30 at 4:54 PM
Flexion Therapeutics to Report First-Quarter 2018 Financial Results on May 8, 2018Flexion Therapeutics to Report First-Quarter 2018 Financial Results on May 8, 2018
finance.yahoo.com - April 30 at 4:54 PM
Flexion Therapeutics (FLXN) Rating Increased to Buy at ValuEngineFlexion Therapeutics (FLXN) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 27 at 1:30 PM
Flexion Therapeutics (FLXN) Rating Increased to Hold at BidaskClubFlexion Therapeutics (FLXN) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - April 27 at 12:13 PM
Flexion up 2% on new Zilretta data in OAKFlexion up 2% on new Zilretta data in OAK
seekingalpha.com - April 26 at 4:57 PM
Flexion Therapeutics to Present Data on ZILRETTA® (triamcinolone acetonide extended-release injectable suspension ...Flexion Therapeutics to Present Data on ZILRETTA® (triamcinolone acetonide extended-release injectable suspension ...
globenewswire.com - April 26 at 8:41 AM
Flexion Therapeutics (FLXN) Presents Updated Results from Clinical Trial Evaluating Repeat Administration of ZILRETTAFlexion Therapeutics (FLXN) Presents Updated Results from Clinical Trial Evaluating Repeat Administration of ZILRETTA
www.streetinsider.com - April 26 at 8:41 AM
Flexion Therapeutics Presents Updated Results from Clinical Trial Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at Osteoarthritis Research Society International World CongressFlexion Therapeutics Presents Updated Results from Clinical Trial Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at Osteoarthritis Research Society International World Congress
finance.yahoo.com - April 26 at 8:41 AM
Flexion Therapeutics to Present Data on ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at the Academy of Managed Care Pharmacy Annual Meeting 2018Flexion Therapeutics to Present Data on ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at the Academy of Managed Care Pharmacy Annual Meeting 2018
finance.yahoo.com - April 24 at 5:13 PM
Flexion Therapeutics (FLXN) Receives Consensus Recommendation of "Buy" from AnalystsFlexion Therapeutics (FLXN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 22 at 5:32 PM
Flexion (FLXN) Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA in Journal of Bone and Joint SurgeryFlexion (FLXN) Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA in Journal of Bone and Joint Surgery
www.streetinsider.com - April 19 at 8:46 AM
Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal of Bone and Joint SurgeryFlexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal of Bone and Joint Surgery
finance.yahoo.com - April 18 at 5:18 PM
 Analysts Expect Flexion Therapeutics (FLXN) Will Announce Quarterly Sales of $2.40 Million Analysts Expect Flexion Therapeutics (FLXN) Will Announce Quarterly Sales of $2.40 Million
www.americanbankingnews.com - April 18 at 4:32 AM
Zacks: Analysts Expect Flexion Therapeutics (FLXN) to Announce -$1.31 Earnings Per ShareZacks: Analysts Expect Flexion Therapeutics (FLXN) to Announce -$1.31 Earnings Per Share
www.americanbankingnews.com - April 16 at 3:24 AM
Flexion Therapeutics Target of Unusually Large Options Trading (FLXN)Flexion Therapeutics Target of Unusually Large Options Trading (FLXN)
www.americanbankingnews.com - April 12 at 7:27 AM
Flexion Therapeutics (FLXN) Earns "Outperform" Rating from Royal Bank of CanadaFlexion Therapeutics (FLXN) Earns "Outperform" Rating from Royal Bank of Canada
www.americanbankingnews.com - April 11 at 2:55 PM
Zacks Investment Research Lowers Flexion Therapeutics (FLXN) to SellZacks Investment Research Lowers Flexion Therapeutics (FLXN) to Sell
www.americanbankingnews.com - April 9 at 11:27 PM
Northland Securities Reiterates Buy Rating for Flexion Therapeutics (FLXN)Northland Securities Reiterates Buy Rating for Flexion Therapeutics (FLXN)
www.americanbankingnews.com - April 8 at 12:40 AM
Flexion Therapeutics (FLXN) Upgraded to Hold by Zacks Investment ResearchFlexion Therapeutics (FLXN) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - April 7 at 3:52 PM
Why Flexion Therapeutics (FLXN) Could Be Positioned for a SlumpWhy Flexion Therapeutics (FLXN) Could Be Positioned for a Slump
www.zacks.com - April 6 at 5:14 PM
Flexion Therapeutics (FLXN) Downgraded to "Sell" at ValuEngineFlexion Therapeutics (FLXN) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 6 at 1:54 PM
Royal Bank of Canada Reiterates "$44.00" Price Target for Flexion Therapeutics (FLXN)Royal Bank of Canada Reiterates "$44.00" Price Target for Flexion Therapeutics (FLXN)
www.americanbankingnews.com - April 4 at 4:44 PM
Small Cap to Large Cap Pharma Companies Positioning to Capitalize on Resurgent Biotech IndustrySmall Cap to Large Cap Pharma Companies Positioning to Capitalize on Resurgent Biotech Industry
www.bizjournals.com - April 4 at 3:49 PM
Form SC 13D/A Rice Midstream Partners Filed by: Harvest Fund Holdco L.P.Form SC 13D/A Rice Midstream Partners Filed by: Harvest Fund Holdco L.P.
www.streetinsider.com - April 4 at 8:50 AM
Flexion Therapeutics (FLXN) Given a $39.00 Price Target at Wells FargoFlexion Therapeutics (FLXN) Given a $39.00 Price Target at Wells Fargo
www.americanbankingnews.com - April 4 at 8:04 AM
Flexion Therapeutics (FLXN) Issued CMS Q code for ZilrettaFlexion Therapeutics (FLXN) Issued CMS Q code for Zilretta
www.streetinsider.com - April 3 at 8:57 AM
$2.80 Million in Sales Expected for Flexion Therapeutics Inc (FLXN) This Quarter$2.80 Million in Sales Expected for Flexion Therapeutics Inc (FLXN) This Quarter
www.americanbankingnews.com - April 1 at 4:42 AM
Flexion Therapeutics (FLXN) Upgraded to "Hold" by ValuEngineFlexion Therapeutics (FLXN) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - March 31 at 2:06 PM
Flexion Therapeutics (FLXN) Downgraded by Zacks Investment Research to SellFlexion Therapeutics (FLXN) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - March 31 at 12:10 PM

SEC Filings

Flexion Therapeutics (NASDAQ:FLXN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Flexion Therapeutics (NASDAQ:FLXN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Flexion Therapeutics (NASDAQ FLXN) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.